Kunle Odunsi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4523591/publications.pdf

Version: 2024-02-01

130	10,194	53794	40979
papers	citations	45 h-index	93 g-index

134	134	134	18064
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intraepithelial CD8⁺tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18538-18543.	7.1	2,100
2	Gene expression markers of Tumor Infiltrating Leukocytes. , 2017, 5, 18.		572
3	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
4	Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nature Communications, 2015, 6, 7458.	12.8	383
5	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
6	Detection of epithelial ovarian cancer using1H-NMR-based metabonomics. International Journal of Cancer, 2005, 113, 782-788.	5.1	322
7	Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE, 2014, 9, e84941.	2.5	279
8	Immunotherapy in ovarian cancer. Annals of Oncology, 2017, 28, viii1-viii7.	1.2	276
9	Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. OncoImmunology, 2017, 6, e1249561.	4.6	252
10	LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget, 2015, 6, 27359-27377.	1.8	242
11	Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12837-12842.	7.1	239
12	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
13	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Research, 2003, 63, 6076-83.	0.9	191
14	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
15	Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5797-5802.	7.1	173
16	Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. Journal of Allergy and Clinical Immunology, 2018, 141, 1028-1035.	2.9	172
17	Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer. Cancer Immunology Research, 2014, 2, 37-49.	3.4	168
18	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157

#	Article	IF	Citations
19	Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenaseâ€"Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer. Cancer Research, 2009, 69, 5498-5504.	0.9	140
20	Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells. Nature Communications, 2017, 8, 14649.	12.8	128
21	Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer. JAMA Oncology, 2021, 7, 78.	7.1	103
22	Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery. JAMA Network Open, 2018, 1, e185452.	5.9	100
23	Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight, 2019, 4, .	5.0	93
24	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clinical Cancer Research, 2018, 24, 1019-1029.	7.0	87
25	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 caseâ€"control studies. Cancer Causes and Control, 2013, 24, 989-1004.	1.8	84
26	Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. Cancer Immunology Research, 2015, 3, 1269-1278.	3.4	84
27	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€"ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
28	Sialic Acidâ€"Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. Journal of Immunology, 2018, 201, 3750-3758.	0.8	77
29	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. British Journal of Cancer, 2014, 111, 2297-2307.	6.4	76
30	PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget, 2016, 7, 45352-45369.	1.8	72
31	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
32	Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. , 2019, 7, 156.		65
33	Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e104099.	2.5	65
34	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
35	A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 5055-5065.	7.0	62
36	Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression. Advances in Experimental Medicine and Biology, 2017, 1036, 129-144.	1.6	62

#	Article	IF	Citations
37	Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. British Journal of Cancer, 2019, 120, 207-217.	6.4	62
38	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecologic Oncology, 2017, 145, 420-425.	1.4	61
39	Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunology Research, 2018, 6, 236-247.	3.4	61
40	Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature. Metabolomics, 2016, 12, 1.	3.0	57
41	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
42	Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Oncotarget, 2015, 6, 27613-27627.	1.8	54
43	The CD47 â€œdon't eat me signalâ€•is highly expressed in human ovarian cancer. Gynecologic Oncology, 2016, 143, 393-397.	1.4	53
44	Synergistic COX2 Induction by IFNÎ³ and TNFÎ± Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunology Research, 2016, 4, 303-311.	3.4	53
45	Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecologic Oncology, 2017, 146, 491-497.	1.4	53
46	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget, 2017, 8, 3197-3205.	1.8	53
47	Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion. Journal of the National Cancer Institute, 2021, 113, 1036-1043.	6.3	50
48	LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecologic Oncology, 2014, 132, 462-467.	1.4	47
49	Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability. Cancers, 2020, 12, 764.	3.7	47
50	Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget, 2015, 6, 11310-11326.	1.8	45
51	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
52	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. Clinical Cancer Research, 2017, 23, 3802-3812.	7.0	43
53	Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget, 2017, 8, 50930-50940.	1.8	43
54	Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro. PLoS ONE, 2012, 7, e51030.	2.5	41

#	Article	IF	Citations
55	Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. , 2019, 7, 189.		41
56	IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation. Frontiers in Immunology, 2021, 12, 678999.	4.8	40
57	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	6.4	39
58	DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Molecular Cancer Research, 2016, 14, 787-794.	3.4	38
59	A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 283-290.	1.4	37
60	Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer. Cancer Immunology Research, 2021, 9, 790-810.	3.4	29
61	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
62	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	1.8	28
63	RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization. Communications Biology, 2021, 4, 102.	4.4	28
64	Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Science Translational Medicine, 2022, 14, eabg8402.	12.4	28
65	Primary primitive neuroectodermal tumor of the uterus: a report of two cases and review of the literature. Gynecologic Oncology, 2004, 92, 689-696.	1.4	27
66	Population-based targeted sequencing of 54 candidate genes identifiesPALB2as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	3.2	26
67	Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils. Cancer Immunology Research, 2020, 8, 819-828.	3.4	25
68	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
69	CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. , 2021, 9, e003329.		25
70	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
71	Epigenetic activation of POTE genes in ovarian cancer. Epigenetics, 2019, 14, 185-197.	2.7	24
72	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23

#	Article	IF	Citations
73	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
74	TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecologic Oncology, 2015, 138, 159-164.	1.4	21
75	Expression of the POTE gene family in human ovarian cancer. Scientific Reports, 2018, 8, 17136.	3.3	21
76	REVIEW ARTICLE: Harnessing the Immune System for Ovarian Cancer Therapy. American Journal of Reproductive Immunology, 2008, 59, 62-74.	1.2	20
77	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. IScience, 2021, 24, 102757.	4.1	20
78	Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget, 2015, 6, 18641-18652.	1.8	20
79	Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Scientific Reports, 2016, 6, 21591.	3.3	18
80	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	6.4	16
81	Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing. BMC Medical Informatics and Decision Making, 2019, 19, 14.	3.0	16
82	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2019, 30, 537-547.	1.8	16
83	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
84	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
85	Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer. ELife, 2021, 10, .	6.0	15
86	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. Clinical Cancer Research, 2021, 27, 5536-5545.	7.0	15
87	A rare population of tumor antigen-specific CD4+CD8+ double-positive Î±Î² T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. , 2019, 7, 7.		14
88	Evaluation of Î²1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer. American Journal of Obstetrics and Gynecology, 2002, 187, 575-580.	1.3	13
89	Tumor-associated macrophages: Co-conspirators and orchestrators of immune suppression in endometrial adenocarcinoma. Gynecologic Oncology, 2014, 135, 173-175.	1.4	13
90	Synuclein-Î³ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. Journal of Ovarian Research, 2016, 9, 75.	3.0	13

#	Article	IF	Citations
91	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
92	Oncologist uptake of comprehensive genomic profile guided targeted therapy. Oncotarget, 2019, 10, 4616-4629.	1.8	13
93	Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecologic Oncology, 2017, 146, 52-57.	1.4	12
94	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
95	Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 1025-1039.	2.2	11
96	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass. Scientific Reports, 2021, 11, 18156.	3.3	11
97	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473.	2.5	10
98	Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy. OncoImmunology, 2016, 5, e1116675.	4.6	9
99	The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. International Journal of Gynecological Cancer, 2017, 27, 11-16.	2.5	9
100	Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer. PLoS ONE, 2018, 13, e0206913.	2.5	9
101	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
102	Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 2573.	4.1	9
103	A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer. Cancer Immunology, Immunotherapy, 2021, 70, 3451-3460.	4.2	9
104	Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. Molecular Therapy - Oncolytics, 2021, 23, 38-50.	4.4	9
105	Evaluation of satisfaction with workâ€“life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study. Gynecologic Oncology Reports, 2016, 16, 17-20.	0.6	8
106	HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecologic Oncology, 2016, 142, 158-162.	1.4	8
107	Use of Common Analgesics Is Not Associated with Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1291-1294.	2.5	7
108	Hereditary association between testicular cancer and familial ovarian cancer: A Familial Ovarian Cancer Registry study. Cancer Epidemiology, 2018, 53, 184-186.	1.9	7

#	Article	IF	Citations
109	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	2.8	6
110	Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics, 2020, 10, 90.	2.6	5
111	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
112	VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 2355-2369.	4.2	5
113	Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2017, 146, 137-145.	1.4	4
114	Anthropometric characteristics and ovarian cancer risk and survival. Cancer Causes and Control, 2018, 29, 201-212.	1.8	4
115	Circulating CD14 + HLAâ€ÐR lo/â˜ monocytic cells as a biomarker for epithelial ovarian cancer progression. American Journal of Reproductive Immunology, 2021, 85, e13343.	1.2	4
116	Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunology, Immunotherapy, 2022, 71, 2881-2898.	4.2	4
117	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
118	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
119	The Great Debate at â€˜Immunotherapy Bridgeâ€™, Naples, December 5, 2019. , 2020, 8, e000921.		3
120	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€•(December 4thâ€“5th,) Tj ETQq0 0 0 rgBT /Over	4.4	3
121	RNA Splicing and Immune-Checkpoint Inhibition. New England Journal of Medicine, 2021, 385, 1807-1809.	27.0	3
122	Immune Checkpoint and Poly(ADPâ€“Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers. JAMA Oncology, 2019, 5, 1103.	7.1	2
123	Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology, 2004, 22, 5018-5018.	1.6	2
124	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	2.5	2
125	Adjuvant treatment for uterine leiomyosarcoma. European Journal of Gynaecological Oncology (discontinued), 2013, 34, 409-14.	0.2	2
126	Tissue residency of memory CD8+ TÂcells matters in shaping immunogenicity of ovarian cancer. Cancer Cell, 2022, 40, 452-454.	16.8	2

#	Article	IF	Citations
127	Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo. Blood, 2011, 118, 2441-2441.	1.4	1
128	Vaccination with NY-ESO-1 in Combination with Decitabine for Patients with MDS. Blood, 2016, 128, 4326-4326.	1.4	1
129	Satisfaction with work-life balance among U.S. gynecologic oncologists, a cross-sectional study. American Journal of Clinical and Experimental Obstetrics and Gynecology, 2015, 2, 166-175.	0.5	1
130	Vaccine therapy for cancer: fact or fiction?. Surgical Technology International, 2004, 13, 39-47.	0.2	0